Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.40 USD
Change Today -0.02 / -0.31%
Volume 526.5K
KERX On Other Exchanges
Symbol
Exchange
KERX is not on other exchanges.
As of 1:38 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KERX) Snapshot

Open
$6.35
Previous Close
$6.42
Day High
$6.68
Day Low
$6.26
52 Week High
09/2/14 - $18.42
52 Week Low
08/24/15 - $5.25
Market Cap
673.1M
Average Volume 10 Days
1.4M
EPS TTM
$-1.36
Shares Outstanding
105.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KERYX BIOPHARMACEUTICALS (KERX)

keryx biopharmaceuticals (KERX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KERX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KERX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

161 Employees
Last Reported Date: 08/6/15
Founded in 1997

keryx biopharmaceuticals (KERX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $358.3K
Compensation as of Fiscal Year 2014.

keryx biopharmaceuticals (KERX) Key Developments

Keryx Biopharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Gross Margin Guidance for the Year 2015

Keryx Biopharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $2.514 million, which included $756,000 royalty payment from JT/Torii related to sales of Riona in Japan in the first quarter of 2015. Operating loss was $26.968 million against $22.543 million a year ago. Loss before income taxes was $26.854 million against $22.414 million a year ago. Net loss was $26.877 million or $0.26 per basic and diluted share against $22.414 million or $0.24 per basic and diluted share a year ago. Total revenues for the second quarter of 2015 represent: Net U.S. Auryxia product revenue of $1.8 million, and License revenue of $756,000 associated with royalties received on ferric citrate sales in Japan related to their net sales during the first quarter of 2015. For the six months, the company reported total revenue of $3.689 million compared with $10.00 million a year ago. Operating loss was $54.571 million against $36.194 million a year ago. Loss before income taxes was $54.571 million against $35.944 million a year ago. Net loss was $54.616 million or $0.53 per basic and diluted share against $35.944 million or $0.40 per basic and diluted share a year ago. The company expects gross margins to remain in the 80% to 85% range over the course of 2015.

Keryx Biopharmaceuticals Inc. to Report Q2, 2015 Results on Aug 05, 2015

Keryx Biopharmaceuticals Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 05, 2015

Keryx Biopharmaceuticals Inc., Q2 2015 Earnings Call, Aug 05, 2015

Keryx Biopharmaceuticals Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KERX:US $6.40 USD -0.02

KERX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KERX.
View Industry Companies
 

Industry Analysis

KERX

Industry Average

Valuation KERX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 148.7x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 120.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.